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Background: Bronchodilator response in patients with asthma is evaluated based on post-bronchodilator increase
in forced expiratory volume in one second (FEV1) and forced vital capacity (FVC). However, the need for additional
parameters, mainly among patients with severe asthma, has already been demonstrated.
Methods: The aim of this study was to evaluate the usefulness of vital capacity (VC) and inspiratory capacity (IC) to
evaluate bronchodilator response in asthma patients with persistent airflow obstruction. The 43 asthma patients
enrolled in the study were stratified into moderate or severe airflow obstruction groups based on baseline FEV1. All
patients performed a 6-minute walk test before and after the bronchodilator (BD). A bipolar visual analogue scale
post-BD was performed to assess clinical effect. The correlation between VC and IC and clinical response,
determined by visual analogue scale (VAS) and 6-minute walk test (6MWT), was investigated.
Results: Patients in the severe group presented: 1) greater bronchodilator response in VC (48% vs 15%, p = 0.02), 2)
a significant correlation between VC variation and the reduction in air trapping (Rs = 0.70; p < 0.01), 3) a significant
agreement between VC and VAS score (kappa = 0.57; p < 0.01). There was no correlation between IC and the
reduction in air trapping or clinical data.
Conclusions: VC may be a useful additional parameter to evaluate bronchodilator response in asthma patients with
severe airflow obstruction.
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Asthma is a serious worldwide health issue, but its clin-
ical manifestations can be controlled with appropriate
treatment [1]. Currently, a positive bronchodilator re-
sponse is established based on an increase ≥ 12% and
200 ml in forced vital capacity (FVC) and/or forced ex-
piratory volume in one second (FEV1) compared with
baseline values following administration of bronchodila-
tors [2]. However, in clinical practice, patients with mod-
erate or severe asthma may refer clinical improvement* Correspondence: karensodre@hotmail.com
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reproduction in any medium, provided the orafter bronchodilator use despite a negative bronchodila-
tor test. In patients with chronic obstructive pulmonary
disease (COPD), in whom the bronchodilator test is fre-
quently negative, vital capacity (VC) and inspiratory cap-
acity (IC) variation are used as complementary tools in
order to evaluate bronchodilator response [3-6]. COPD
patients have a persistent airway obstruction that may
also be observed in moderate or severe asthma; however,
only a few studies so far have evaluated the usefulness of
VC and IC to assess bronchodilator response among
asthmatic patients [7-13].
The aim of this study was to analyze the usefulness of
VC and IC as additional parameters to assess broncho-
dilator response in asthma patients with moderate or se-
vere airflow obstruction.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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This study prospectively enrolled patients aged 15 years
and older diagnosed with asthma and persistent airway
obstruction according to Global Initiative for Asthma
(GINA) criteria, and who were clinically stable at the
time of enrollment [14]. Subjects were not eligible if they
were current or former smokers (≥ 20 packs) or had
clinical and/or radiographic evidence of heart failure,
uncontrolled systemic arterial hypertension, pregnancy,
focal fibrous scarring on chest X-ray with total area ≥ 1
pulmonary lobe, chest wall deformity or articular or
neuromuscular disease, morbid obesity or previous lung
resection. Also excluded were patients who used short-
acting β2-agonist spray, long-acting β2-agonist spray or
oral theophylline 8 h, 12 h or 48 h respectively before
the pulmonary function tests, and patients experiencing
an asthma crisis or exacerbation during the week before
the pulmonary function tests. All patients were referred
from the Outpatient Asthma Clinic at the Federal Uni-
versity of Rio de Janeiro Institute of Thoracic Diseases
(ITD). They were evaluated at the ITD Pulmonary Func-
tion between June 19, 2006 and July 30, 2008. Written
informed consent was obtained from all participants (or
a legally responsible representative when applicable) and
the study was approved by the Federal University of Rio
de Janeiro Ethics Committee.
All patients answered a standardized interview and
underwent physical examination as well as lateral decubi-
tus and posteroanterior chest x-ray before the broncho-
dilator test [14]. Pulmonar function tests (PFTs) and a 6-
minute walk test (6MWT) were performed before and
15 minutes after the bronchodilator test. Only one
6MWT was done before and after the bronchodilator. A
bipolar visual analogue scale (VAS) was used to assess the
perceived effect of the bronchodilator test on shortness of
breath. The bronchodilator test was performed with salbu-
tamol/400 μg spray under physician supervision (KRSA).
PFTs included flow-volume and volume-time curves, in-
spiratory slow vital capacity maneuver and determination
of static lung volumes using a Jaeger spirometer (model
MasterScreen-PTF, Hoechberg, Germany), and were con-
ducted according to American Thoracic Society (ATS)/
European Respiratory Society (ERS) guidelines [15,16].
Static lung volumes were calculated using the closed-
circuit helium dilution method. For He-derived TLC, the
end-of-test criterion (equilibration) was defined as helium
concentration change of 0.02% or less during 30s re-
breathing. The predicted normal values for spirometry
and lung volumes were those of Knudson et al. [17]. Pol-
gar/Promadhat and Goldman/Becklake [18,19] respect-
ively. The 6MWT was performed following ATS
guidelines, with dyspnea score based on a Borg scale [20].
For the VAS, patients were asked to indicate on a
100 mm horizontal line, labeled “very much worse” onthe left end (−100), “very much better” on the right end
(+100) and “no change” (zero) in the middle, after the
bronchodilator test [21]. Bronchodilator response was
defined as an increase in FEV1 or FCV ≥ 12% of the
baseline value plus 200 ml [2], or a decrease in residual
volume (RV) ≥ 20% of the predicted value and 300 ml
compared with baseline [22]. Clinical bronchodilator re-
sponse was defined as 6MWD ≥ 50 meters or at least 30
meters associated with a reduction greater than 2 points
in the Borg scale score [5,20], or any positive value in
VAS. For VC and IC, an increase ≥ 12% and 200 ml com-
pared with baseline indicated a positive bronchodilator
test.
Asthma patients were stratified into two groups
according to the value of FEV1: moderate (60%< FEV1 <
80% of predicted values) and severe airflow obstruction
(FEV1≤ 60% of the predicted values), according to GINA
criteria [14].Statistical analysis
The Mann–Whitney test was used for quantitative data,
and the chi-square test for qualitative parameters. The
correlation between the variation in VC and IC and the
variation in residual volume-to-total lung capacity ratio
(RV/TLC) was analyzed using Spearman’s correlation
test. The agreement between VC and IC responses and
clinical response was analyzed using the Kappa coeffi-
cient. The classification proposed by Chan and Byrt for
the interpretation of Spearman and Kappa values re-
spectively, was adopted [23,24]. The statistical package
for the social sciences (SPSS) v. 13.0 was used, and a
p < 0.05 was considered significant.Results
During the study period, 60 subjects were screened and
43 (72%) were enrolled: 20 had moderate airflow ob-
struction and 23 had severe airflow obstruction. Demo-
graphic, clinical and radiological parameters are
presented in Table 1. Spirometry, 6MWT, and VAS were
performed in all patients, while static lung volumes were
analyzed in 37 patients. Functional data for patients with
moderate and severe obstruction before (Pre) and after
(Post) the bronchodilator (BD), test are depicted in
Table 2. VC, IC, FVC, and FEV1 were significantly lower
in the group with severe airflow obstruction vs. the
group with moderate airflow obstruction. Conversely,
pre-BD RV/TLC ratio was increased in the presence of
severe airflow obstruction. After BD, a significant in-
crease in VC, IC, FVC and FEV1 was observed in both
groups as well as a significant reduction in RV/TLC ratio
in severe group. A significant increase in 6MWT dis-
tance and a decrease in dyspnea score (Borg scale) were
observed after the BD in both groups (Table 3).
Table 1 Demographic and clinical characteristics of asthma patients
Parameters Moderate airflow obstruction (n= 20) Severe airflow obstruction (n= 23) P
Age (years) 50 (37–61) 56 (45–65) 0.32
Height (cm) 156 (152–163) 156 (153–161) 0.76
Weight (kg) 70.6 (58.7-78.9) 67.6 (54.7-72.2) 0.38
Male/Female 6/14 4/19 0.33
Dyspnea score (Borg scale) 0 (0–3.3) 3 (0–5) 0.12
Treatment (Standard/Others) 13/7 20/3 0.09
Standard treatment: regular inhaled corticosteroids and long-acting β2-agonists.
p value – Mann Whitney test for quantitative data and Chi-square for qualitative data. Quantitative data are expressed as median (25th percentile-75th percentile).
Azevedo et al. BMC Pulmonary Medicine 2012, 12:49 Page 3 of 6
http://www.biomedcentral.com/1471-2466/12/49If considering the ATS/ERS definition of obstructive
abnormalities, FEV1/VC < 5th percentile of predicted
value, only 2 patients did not fulfill this criterion, al-
though they have FEV1 values below 80%, respectively
79.3 and 69.0%.Table 2 Pulmonary function before and after bronchodilator
Parameters % P or L Moderate airflow obstruction (n= 20)
VC
Pre-BD (%P) 93.2 (86.5-101.0)
Post-BD (%P) 102 (91.4-104.7)
P (Wilcoxon) 0.01
IC
Pre-BD (L) 1.94 (1.63-2.43)
Post-BD (L) 2.1 (1.73-2.63)
P (Wilcoxon) 0.02
FVC
Pre-BD (%P) 96.2 (88.1-104.3)
Post-BD (%P) 105.2 (92.3-109.7)
P (Wilcoxon) <0.01
FEV1
Pre-BD (%P) 68.2 (65.3-77.5)
Post-BD (%P) 78.9 (70.7-86.3)
P (Wilcoxon) <0.01
TLC
Pre-BD (%P) 95.8 (91.4-113.5)
Post-BD (%P) 99.2 (89.9-109.4)
P (Wilcoxon) 0.8
RV/TLC
Pre-BD (%P) 108.1 (97.6-123.9)
Post-BD (%P) 101.0 (79.7-122.4)
P (Wilcoxon) 0.1
RV
Pre-BD (% P) 105.2 (90.0-136.6)
Post-BD (% P) 97.3 (76.3-135.6)
P (Wilcoxon) 0.3
BD=bronchodilator, FEV1 = forced expiratory volume in one second, FVC = forced v
volume, TLC = total lung capacity, VC = vital capacity. Results are expressed as mediVC response was observed in 11 (48%) patients with
severe obstruction and three (15%) with moderate ob-
struction (p = 0.02). No significant changes were
observed between the two groups in the percentage of
bronchodilator response for the other parameters.of asthma patients






















ital capacity, IC = inspiratory capacity, L = liters, P = predicted, RV = residual
an (25th percentile-75th percentile). p value for paired sample – Wilcoxon test.
Table 3 6-minute walk test results before and after bronchodilator of asthma patients
Parameters Moderate airflow obstruction (n= 20) Severe airflow obstruction (n= 23) P (Mann Whitney)
6WTD
Pre-BD (m) 515 (479–570) 501 (468–537) 0.26
Post-BD (m) 555 (511–588) 519 (480–570) 0.26
P (Wilcoxon) <0.01 <0.01
Borg Scale
Pre-BD 5 (0–6) 5 (3–7) 0.35
Post-BD 3 (0–5) 3 (1–4) 0.86
P (Wilcoxon) 0.03 <0.01
6WTD= 6 minute walk test distance, m=meters, BD =bronchodilator. Results are expressed as median (25th percentile-75th percentile). p value for paired sample –
Wilcoxon test.
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parameters and the variation in RV/TLC (% predicted
values) before and after BD were performed and we
observed a significant negative correlation between VC
and RV/TLC in the severe airflow obstruction group
[Spearmans rank correlation coefficient (Rs) =−0.70,
p < 0.01], and between FVC and RV/TLC in patients
with moderate obstruction (Rs =−0.55, p = 0.03). Con-
versely, there was no correlation between IC and RV/
TLC. Agreement analyses for functional and clinical
parameters after BD use are presented in Table 4. There
was a fair agreement between VC (severe group) and
FVC (moderate group) response and VAS scores, and a
slight agreement between RV response (severe group)
and VAS score. There was no agreement between func-
tional parameter responses and improvement in 6MWT.
There was a poor correlation (p = 0.35) between varia-
tions in VC versus variation in VAS in severe obstruction
patients, and between IC and VAS (p = 0.28) in moderate
group.
Five patients with positive VC and/or IC response pre-
sented a negative FVC and/or FEV1 response.Discussion
In the present study with asthma patients with moderate
and severe obstruction, we observed that VC may be aTable 4 Analysis of agreement between functional and clinica
VAS




VC 0.20 (0.14) 0.57 (<0.01)
IC 0.10 (0.61) 0.22 (0.17)
FVC 0.40 (0.03) 0.34 (0.06)
FEV1 0.10 (0.65) 0.06 (0.75)
RV 0.10 (0.61) 0.32 (0.04)
6MWT= six-minute walk test, FEV1 = forced expiratory volume in one second, FVC =
analogue scale, VC= vital capacity. Results are expressed as Kappa coefficient and puseful complementary parameter to FVC and FEV1 to
assess bronchodilator response.
Asthma patients were assigned to a moderate or severe
airflow obstruction group based on FEV1 analysis. In
addition, because clinical improvement is the main goal
of asthma therapy, VAS (subjective criterion) and
6MWT (objective criterion) were also used to evaluate
clinical bronchodilator response in this study [20,21,25].
Paré et al. have described two patterns of response to
bronchodilator therapy: predominant increase in expira-
tory flow rate (flow responders) or FVC (volume respon-
ders). Volume responders presented lower expiratory
flows and greater degree of air trapping [7]. Newton
et al., also reported similar results [22]. More recently,
Sorkness et al., studying 287 patients with stable but se-
vere asthma, demonstrated that this group presented
prominent air trapping in contrast to individuals with
non-severe asthma [12]. Our patients with severe airflow
obstruction had both greater VC response in the group
and greater air trapping (Table 2).
The 6MWT is considered a good parameter to esti-
mate exercise tolerance in patients with moderate or se-
vere pulmonary impairment, even though it has not
been extensively used in asthma patients [20]. In our
patients a significant increase in 6WTD as well as a de-
crease in Borg scale were observed in both groups
(Table 3). We made only one 6MWT before and afterl positive responses after bronchodilator use
6WT






0.00 (1.0) 0.04 (0.86)
−0.05 (0.80) −0.05 (0.83)
0.20 (0.37) 0.12 (0.55)
forced vital capacity, IC = inspiratory capacity, RV = residual volume, VAS = visual
value in parenthesis.
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been considered excellent [20].
The post-BD response of VC was well correlated with
the variation in RV/TLC ratio in the severe obstruction
group. In this line, O’Donnell et al. studied 84 patients
with obstructive disease without response in FEV1 and
found a good correlation between variation in VC and
IC and FRC after use of bronchodilator [6]. Additionally,
Newton et al. demonstrated that lung volume improve-
ment was independent of changes in maximal expiratory
flows in patients with moderate and severe hyperinfla-
tion [22].
Agreement between VAS scores and functional
responses was statistically significant in only three para-
meters, VC and RV in the severe obstruction group and
FVC in the moderate obstruction group, without agree-
ment with IC response (Table 4). This is in accordance
with previous studies reporting a better correlation be-
tween dyspnea and the volume of thoracic gas rather
than FEV1 [9,10,13]. A poor correlation (p = 0.35) was
observed between variations in VC versus variation in
VAS in severe obstruction patients. Probably, the reduc-
tion in air trapping is not enough to improve exertional
breathlessness without a simultaneous and marked de-
crease in end-expiratory lung volume. Moreover, the in-
crease in VC and IC may represent unrelated effects of
the bronchodilation. VAS has been shown to be sensitive
to detect improvement in asthma patients [26].
FEV1 is considered a good marker of improvement.
However, in patients with severe airflow obstruction,
FEV1 presents a lack of sensitivity and is a poor pre-
dictor of improvement in exercise tolerance [22,27-29].
Moreover, Teeter and colleagues demonstrated that
asthma symptoms were poorly correlated with FEV1 be-
fore and after therapy [30]. Therefore, in addition to
FEV1, other physiologic parameters, such as lung elastic
recoil, should be considered to characterize asthma se-
verity [31].
This study has some limitations that need to be
addressed: 1) we were not able to correlate the reduction
in air trapping with the increase in IC measured in rest,
as previously described during exercises tests [3,9,29] or
during methacholine challenge testing [8,11] and 2) static
lung volumes were measured using the helium dilution
method, even though body plethysmography is consid-
ered the most sensitive method [25,32]. However, we
opted to use more routine tests because ergospirometry,
bronchoprovocation test and plethysmography are not
available in most pulmonary function laboratories.
Conclusions
The present findings suggest that VC may be useful in
addition to FVC and FEV1 to identify bronchodilator re-
sponse in asthma patients with severe airflow obstruction.Competing interests
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